[Activity of a new long-acting anti-arrhythmic drug on ventricular extrasystole. Study with Holter continuous electrocardiographic monitoring].
Therapeutic effectiveness of a new long-acting antiarrhythmic preparation was evaluated in 31 patients with sustained premature ventricular beats. After an observation period, a 24 hours Holter monitoring was performed. A group (21 patients) was treated with dihydrochinidine 250 mg twice a day; another group (11 patients) was treated with 500 mg twice a day. In the latter group was determined basal chinidinemia on the first and third day. A 24 hours Holter monitoring was repeated on the fourth day. In the first group we reached a 77.4% reduction of the arrhythmia: not enough, however, to agree with established statements. We reached a larger reduction (84.7%) with higher doses (1000 mg daily). This drug was well tolerated in both groups.
D000328:Adult; D000368:Aged; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004562:Electrocardiography; D006321:Heart / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D008991:Monitoring, Physiologic; D011802:Quinidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D003692:Delayed-Action Preparations; C014486:hydroquinidine; D011802:Quinidine
Attività di un nuovo antiaritmico "long-acting" sull'extrasistolia ventricolare. Studio con il monitoraggio elettrocardiografico continuo di Holter.